ArticleCurrent medicinal chemistry2026
Comprehensive Exploration of NOTCH2NLA Across Cancers and Its Potential Roles in Prognosis and Immune System Interactions.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNOTCH2NLA is a newly identified gene that has recently emerged as a potential key regulator in cancer biology. Although evidence suggests its biological significance, its roles across different cancer types and clinical relevance remain poorly characterized. This study aims to comprehensively investigate the functional value of NOTCH2NLA across multiple cancer types. MATERIALS AND
methodsUsing advanced bioinformatics tools and publicly available datasets, we analyzed the expression profiles of NOTCH2NLA, assessed its prognostic value for survival outcomes, and examined its role in immune regulation and cancer-related signaling pathways. Genetic alterations and immune infiltration patterns were further explored to evaluate its potential role in tumor development.
resultsNOTCH2NLA exhibited differential expression patterns across various cancer types, with its expression levels significantly correlated with patient survival. Additionally, NOTCH2NLA was found to interact with immune cells, modulate immune infiltration, and participate in key biological processes essential for cancer progression. DISCUSSION: The findings suggest that NOTCH2NLA plays a multifaceted role in cancer biology, particularly through involvement in immune-related pathways. These results underscore the importance of further exploring how NOTCH2NLA contributes to immune evasion and tumor progression.
conclusionThis study provides comprehensive insights into the pan-cancer functions of NOTCH2NLA and supports its potential as a promising target for personalized cancer therapies.
Indexed as
Identifiers
42803163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.